COVID-19 Response

Powering the next breakthrough with 36 studies to advance vaccines and therapeutics to treat coronavirus as well as the launch of a novel information gathering portal with more than 50 reports to date

Using ”Human Data Science” to Power Breakthroughs

IQVIA has been awarded more than 36 study mandates to help advance vaccines and therapeutics for COVID-19.

Weekly Webcast

Monitoring the Impact of COVID-19 on the Pharmaceutical Market - Weekly

White Paper

The Impact of the COVID 19 Pandemic on Global Pharmaceutical Growth

Bridging Collaboration with Cutting-Edge Research

The company launched the COVID Active Research Experience (CARE) Project, an information-gathering portal, which to date has produced more than 50 reports to help inform the scientific community and the greater community at large about disease prevalence, symptom progression and treatment outcomes.

Featured article

How the global pharmaceutical and biotech sector is  responding to COVID-19


IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.


Hit enter to search or ESC to close